HARRISBURG – Attorney General Dave Sunday announced that Pennsylvania is part of an approximately $720 million combined national settlement with eight drug manufacturers that worsened the nationwide opioid crisis.
Based on the overwhelming participation by Attorneys General across the country, all eight company defendants have agreed to proceed with a sign-on period for local governments. Pennsylvania could receive up to $28 million, dependent on how many local governments participate in the proposed settlement.
This latest settlement comes on the heels of a $7.4 billion settlement reached with Purdue Pharma and the Sackler family that will bring as much as $200 million to the Commonwealth.
“These funds come out of the pockets of companies that contributed to the nationwide addiction epidemic and into Pennsylvania communities,” Attorney General Sunday said. “One of my top priorities is to support counties in their efforts to provide people and families with prevention, treatment, and recovery resources — this money will do just that.”
The eight company defendants (and their payment shares) are:
- Mylan (now part of Viatris): $284,447,916 paid over nine years
- Hikma: $95,818,293 paid over one to four years
- Amneal: $71,751,010 paid over 10 years
- Apotex: $63,682,369 paid in a single year
- Indivior: $38,022,450 paid over four years
- Sun: $30,992,087 paid over one to four years
- Alvogen: $18,680,162 paid in a single year
- Zydus: $14,859,220 paid in a single year
In addition to these abatement payments, several of the settlements allow states to receive free pharmaceutical products or cash in lieu of this product.
Additionally, seven of the companies (not including Indivior) are prohibited from promoting or marketing opioids and opioid products, making or selling any product that contains more than 40 mg of oxycodone per pill, and putting in place a monitoring and reporting system for suspicious orders. Indivior has agreed to not manufacture or sell opioid products for the next 10 years, but it will be able to continue marketing and selling medications to treat opioid use disorder.
# # #